Foghorn Therapeutics Appoints Biotech Veteran Ryan Maynard as CFO
Event summary
- Ryan Maynard joins Foghorn Therapeutics as Chief Financial Officer on February 23, 2026.
- Maynard brings over 25 years of experience in financial strategy and capital markets execution in biotech.
- Previously CFO at Cara Therapeutics, where he led a reverse merger and raised $37.5 million.
- Foghorn's lead program, FHD-909, is in dose escalation with Lilly, and its degrader portfolio nears clinical trials.
The big picture
Foghorn Therapeutics strengthens its financial leadership with the appointment of Ryan Maynard, a seasoned biotech executive. This move comes as the company advances its first-in-class pipeline, including a partnership with Lilly for its lead program. Maynard’s track record in scaling organizations and executing strategic transactions positions Foghorn to navigate the complexities of clinical development and capital markets in the competitive biotech landscape.
What we're watching
- Financial Strategy
- How Maynard’s experience in capital raising and strategic transactions will shape Foghorn’s financial strategy.
- Clinical Progress
- The pace at which Foghorn’s lead program, FHD-909, advances through clinical trials in partnership with Lilly.
- Operational Scaling
- Whether Maynard’s operational leadership can accelerate Foghorn’s mission to deliver novel therapies.
Related topics